ClinicalTrials.gg
CompletedNCT06646302Updated Oct 27, 2026

Residual Inhibition of 40 Hz Burst Sound in Tinnitus Patients

An interventional study of Personalized 40 Hz Broadband Stimulation and 40 Hz Pure Tone Stimulation in Tinnitus, sponsored by Eye & ENT Hospital of Fudan University. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Eye & ENT Hospital of Fudan University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 27, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Tinnitus by Eye & ENT Hospital of Fudan University — 4 open to participants now, 4 under way, none of them phase 3. Tinnitus · Eye & ENT Hospital of Fudan University.

Enrollment
Largest of 11
363 · median 162
Started
2024
with 1 other
No phase
11 of 12
4 open now
Registered
7th of 12
by date

Among the 12 studies in Tinnitus by Eye & ENT Hospital of Fudan University, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 with no phase, and was the 7th registered.

Tinnitus

446 studies on the registry are indexed under Tinnitus; 98 are open to participants now.

Browse Tinnitus studies →

Open to participants now

4 of the 12 studies in Tinnitus by Eye & ENT Hospital of Fudan University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 49 Tinnitus studies recruiting now, 21 (43%) set no upper age limit and 18 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Tinnitus by Eye & ENT Hospital of Fudan University, or all of them as a file.
02

Study summary

Tinnitus affects 10-15% of adults and is frequently associated with impaired quality of life, anxiety, and sleep disturbance. Conventional sound therapies based on continuous masking provide inconsistent and short-lived relief, and the neural mechanisms underlying residual inhibition (RI) remain unclear.

This study aims to determine whether 40 Hz burst stimulation with high-frequency carriers can achieve longer-lasting RI than continuous sound, and to explore its underlying neural mechanisms using EEG.

Read the detailed description

Residual inhibition (RI) refers to the temporary reduction or disappearance of tinnitus following sound stimulation and provides an important clue for identifying patients who may benefit from acoustic therapy. However, the effects of different sound stimulation strategies on RI remain poorly understood.

This study evaluates whether 40 Hz burst-modulated sound achieves stronger and longer RI compared with conventional continuous stimulation. The trial follows a four-phase design:

Phase 1: Exploratory testing of burst versus continuous tones at different frequencies.

Phase 2: Large-scale validation in 265 patients. Phase 3: Development of a personalized stimulation protocol using adaptive spectral optimization.

Phase 4: An independent EEG cohort undergoing a randomized crossover comparison of personalized burst and continuous broadband stimulation to investigate changes in gamma-band functional connectivity associated with residual inhibition.

The primary outcomes are the strength and duration of tinnitus suppression. Secondary outcomes include EEG-derived measures of source-space functional connectivity, quantified using phase-locking value (PLV) in the gamma band (38-42 Hz).

By combining behavioral and neurophysiological measures, this study aims to establish 40 Hz burst stimulation as a novel rhythm-based sound therapy and to provide mechanistic insights that may enable more effective, personalized tinnitus management.

03

Conditions studied

  • Tinnitus

Browse trials for

Keywords

  • Tinnitus
  • 40 Hz stimulation
  • Acoustic therapy
  • Residual inhibition
  • Personalized medicine
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with subjective tinnitus;
  2. Chronic tinnitus: tinnitus course ≥ 1 month;
  3. Normal middle ear function;
  4. The average hearing threshold (defined as mean of 0.5, 1, 2, and 4 kHz) of the unaffected ear \< 60 dB;
  5. Tinnitus can be heard under normal circumstances.
  6. Subjects are able to understand the purpose of the study, volunteer to participate and cooperate with the instructors to complete the experiment, and be willing to sign the .

Exclusion criteria

Exclusion Criteria:

  1. Acute phase tinnitus;
  2. Fluctuating tinnitus loudness;
  3. Severe psychiatric disorders;
  4. Inability to complete tinnitus testing;
  5. Fluctuating or retrocochlear hearing loss;
  6. Conductive hearing loss;
  7. Currently participating in other research projects that may affect tinnitus;
  8. Subjects who are not considered suitable for this clinical trial by the researchers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    Personalized 40 Hz Broadband Stimulation

    Participants receive personalized broadband acoustic stimulation modulated at 40 Hz. An adaptive equalization algorithm, based on individual and population residual inhibition (RI) responses, is used to weight frequency components across 125 Hz-12 kHz.

    Other: Personalized 40 Hz Broadband Stimulation

  • Experimental
    40 Hz Pure Tone Stimulation

    Participants receive pure tone stimulation at the individually optimized carrier frequency identified in earlier phases, amplitude-modulated at 40 Hz.

    Other: 40 Hz Pure Tone Stimulation

  • Active comparator
    Continuous Broadband Noise

    Participants receive continuous broadband noise stimulation without 40 Hz modulation.

    Other: Continuous Broadband Noise

Interventions

  • OtherPersonalized 40 Hz Broadband Stimulation

    Broadband acoustic stimulus (125 Hz-12 kHz) amplitude-modulated at 40 Hz with a 50% duty cycle. A polynomial regression and FFT-based algorithm applies individualized frequency weighting, combining population data (70%) and patient-specific responses (30%). Delivered for 60 seconds at 10 dB above the individual minimum masking level (MML).

  • Other40 Hz Pure Tone Stimulation

    Pure tone stimulus at the optimized frequency (matched to tinnitus characteristics or high-frequency carrier), amplitude-modulated at 40 Hz with a 50% duty cycle. Delivered for 60 seconds at 10 dB above MML.

  • OtherContinuous Broadband Noise

    Continuous broadband noise spanning 125 Hz-12 kHz without 40 Hz modulation. Delivered for 60 seconds at 10 dB above MML as an active control condition.

06

What researchers measure

Primary outcomes

  1. Tinnitus suppression strength

    Residual inhibition depth, 0-100% reduction

    Time frame: Immediately after the sound stimulation session.

  2. Residual inhibition duration

    Time in seconds until tinnitus returns to baseline after stimulation

    Time frame: Immediately after the sound stimulation session.

Secondary outcomes

  1. EEG functional connectivity changes

    Changes in source-space functional connectivity quantified using phase-locking value (PLV) in the gamma band (38-42 Hz), comparing stimulation and post-stimulation periods with baseline.

    Time frame: measured across the entire 10-minute EEG recording session (baseline, during stimulation, and post-stimulation)

07

Study locations

1 site
  • Eye & ENT Hospital of Fudan University
    Shanghai, Shanghai Municipality 200031, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Feb 2026, 15 months.

Of 134 non-industry interventional studies with no phase under Tinnitus, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's 15 months is below that.

Counting every sponsor, half of 153 studies reached it within 17 months; a quarter within 10 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Jul 2025 → Feb 2026 and completion Jul 2025 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 17, 2024
StartActual
Oct 28, 2024
Primary completionActual
Feb 11, 2026was Jul 2025
CompletionActual
Feb 11, 2026was Jul 2025
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 18, 2025→Feb 11, 2026
Oct 27, 2026
Study completion
Jul 18, 2025→Feb 11, 2026
Oct 27, 2026
Enrollment
265→363
Oct 27, 2026
Secondary outcomes
1 removed, 1 description edited
What changed in the outcomes
  • RemovedEEG spectral power changesTime frame: measured across the entire 10-minute EEG recording session (baseline, during stimulation, and post-stimulation)
  • DescriptionEEG functional connectivity changes: how it is measured was reworded
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Jul 18, 2025→Feb 11, 2026
    Study completion Jul 18, 2025→Feb 11, 2026
    Enrollment 265→363
    Secondary outcomes 1 removed, 1 description edited
    What changed in the outcomes
    • RemovedEEG spectral power changesTime frame: measured across the entire 10-minute EEG recording session (baseline, during stimulation, and post-stimulation)
    • DescriptionEEG functional connectivity changes: how it is measured was reworded
    + 5 other changes: identifiers, verification date, oversight details, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06646302
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Oct 28, 2024
Primary completion
Feb 11, 2026
Completion
Feb 11, 2026
Last update
Oct 27, 2026

Study contacts

Huawei Li, PhD
principal investigator · Eye & ENT Hospital of Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion